Company Profile

Litron Laboratories (AKA: Litron Laboratories Ltd)
Profile last edited on: 10/31/2023      CAGE: 0WSM9      UEI: LJH7LE9AUHL5

Business Identifier: State-of-the-art flow cytometric methods
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3500 Winton Place
Rochester, NY 14623
   (585) 442-0930
Location: Single
Congr. District: 25
County: Monroe

Public Profile

In business since 1976 and active in the SBIR arena from the first few years of the program's functioning, Litron provides critical data to pharmaceutical, medical device, government and contract research organizations worldwide. Organized around DNA damage and other toxic effects, principals of the firm develop state-of-the-art flow cytometric methods to solve challenging problems for the toxicology industry. With an emphasis on safety testing of new compounds and devices, Litron offers genetic toxicology service. Current research includes an developing a flow cytometric method for scoring in vitro micronuclei and measuring micronuclei in human peripheral blood. The firm is a genetic toxicology research and testing company focusing on the safety testing of drugs and medical devices. Patented MicroFlow® kits (for research use only) use a few drops of blood from a mouse, rat or human for rapid accurate analysis of DNA damage (which is related to long-term cancer risk). These kits offer both speed and objectivity using high speed flow cytometry.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,832,396
Project Title: High Throughput Screen and High Information Follow-Up Tests for Genotoxicants
2020 2 NIH $1,135,816
Project Title: Next Generation Testing Strategies for Assessment of Genotoxicity
2020 1 NIH $176,622
Project Title: Development of Rat Liver 3d Organoid Methods to Address Genotoxicity Screening
2019 2 NIH $1,419,108
Project Title: Validation of Cross-Species Biomarkers of DNA Damage
2018 2 NIH $1,132,703
Project Title: Automation of a Liver Genotoxicity Assay

Key People / Management

  Carol Tometsko -- President

  Stephen D Dertinger

  Francis G Murante

  Andrew M Tometsko -- Director of Business Development

  Dorothea K Torous

Company News

There are no news available.